

# 18/ 508  
10/17/01  
PATENT

Attorney Docket No. 3495.0111-10  
Customer No. 22,852

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re Application of: )  
Bernard DUJON et al. ) Group Art Unit: 1633  
Serial No.: 09/244,130 ) Examiner: KAUSHAL, S.  
Filed: February 4, 1999 )

For: NUCLEOTIDE SEQUENCE ENCODING  
THE ENZYME I-SCEI AND THE USES THEREOF

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

**RESPONSE TO PAPER NO. 15**

RECEIVED  
OCT 15 2001  
TECH CENTER 1600/2900

In response to the Office Action dated April 11, 2001 (Paper No. 15), the period for response to which has been extended by filing a petition for three month extension of time concurrently herewith, applicants submit the following remarks.

**REMARKS**

Reconsideration of this application is respectfully requested.

Applicants thank Examiner Kaushal and Primary Examiner Clark for the courtesy of the Interview on June 20, 2001.

Claims 53-57 were provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 15, 28-30, and 32 of copending Application No. 08/643,732. Since this is a provisional rejection, applicants respectfully request that the rejection be held in abeyance.

Claims 48-93 were rejected under 35 U.S.C. § 112, first paragraph, for allegedly containing subject matter that was not described in the specification in such a way as to

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N. W.  
WASHINGTON, DC 20005  
202-408-4000